Merck & Co Inc
6MK
Company Profile
Business description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Contact
126 East Lincoln Avenue
RahwayNJ07065
USAT: +1 908 740-4000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
75,000
Stocks News & Analysis
stocks
Avoid this overvalued ASX lithium producer
Why the market may be overpricing future earnings for this lithium producer.
stocks
Morningstar's verdict on SpaceX
Mark and Shani run through the business and what our analysts think about the IPO.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,014.10 | 12.20 | 0.14% |
| CAC 40 | 8,340.71 | 59.40 | -0.71% |
| DAX 40 | 24,893.58 | 246.11 | -0.98% |
| Dow JONES (US) | 51,666.84 | 45.87 | -0.09% |
| FTSE 100 | 10,428.85 | 9.00 | -0.09% |
| HKSE | 23,477.93 | 141.65 | 0.61% |
| NASDAQ | 25,587.04 | 579.56 | -2.21% |
| Nikkei 225 | 69,528.51 | 259.88 | -0.37% |
| NZX 50 Index | 13,400.66 | 35.11 | -0.26% |
| S&P 500 | 7,365.46 | 107.33 | -1.44% |
| S&P/ASX 200 | 8,811.80 | 10.40 | 0.12% |
| SSE Composite Index | 4,110.70 | 4.45 | 0.11% |